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Abstract
 Objective—To examine the association between risk perceptions after human papillomavirus 
(HPV) vaccination and sexual behaviors and sexually transmitted infection (STI) diagnosis over 
30 months following vaccination.
 Methods—Participants included 112 sexually experienced girls aged 13–21 years who were 
enrolled at the time of first HPV vaccination and completed ≥2 of 4 follow-up visits at 2, 6, 18, 30 
months and including 30 months. At each visit, participants completed surveys assessing risk 
perceptions (perceived need for safer sexual behaviors, perceived risk of STIs other than HPV) and 
sexual behaviors. STI testing was done at 6, 18, and 30 months. Outcomes were condom use at last 
intercourse with main male partner, number of sexual partners since last study visit, and STI 
diagnosis. Associations between risk perceptions and sexual behaviors/STIs were examined using 
generalized linear mixed models.
 Results—Mean age was 17.9 years; 88% were Black; 49% had a history of STI at baseline. 
Scale scores for perceived need for safer sexual behaviors did not change significantly over time. 
Scale scores for perceived risk of STIs other than HPV significantly changed (p=0.027), indicating 
that girls perceived themselves to be more at risk of STIs other than HPV over 30 months 
following vaccination. Multivariable models demonstrated that greater perceived need for safer 
sexual behaviors following vaccination was associated with condom use (p=0.002) but not with 
number of partners or STI diagnosis. Perceived risk of STIs other than HPV was not associated 
with the three outcomes.
 Conclusions—The finding that perceived risk for STIs other than HPV was not associated 
with subsequent sexual behaviors or STI diagnosis is reassuring. The association between 
perceived need for safer sexual behaviors and subsequent condom use suggests that the HPV 
vaccination visit is an important opportunity to reiterate the importance of safer sexual behaviors 
to sexually experienced girls.
Keywords
Papillomavirus vaccines; Adolescent; Sexual behavior; Longitudinal study; Survey study; Sexually 
transmitted infections (STIs)
 Introduction
Despite published Advisory Committee on Immunization Practices (ACIP) 
recommendations for routine prophylactic vaccination against human papillomavirus (HPV) 
for girls since 2007,[1] overall uptake remains suboptimal.[2] One contributing factor may 
be concern about the impact of vaccination on sexual behaviors. Concerns have been raised 
by parents[3–7] and clinicians[8, 9] that some girls who received the HPV vaccine may 
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incorrectly perceive themselves to be at less risk of sexually transmitted infections (STIs) 
other than HPV and thus may engage in riskier sexual behaviors.
Risk homeostasis theory proposes that individuals adjust their behavior based on their 
perceived level of risk of an outcome (risk perceptions) and the level of risk that they are 
willing to assume.[10, 11] This theory has been used to examine sexual behaviors among 
people who are at risk of STIs and human immunodeficiency virus (HIV) infection. The 
theory posits that individuals who perceive that their risk of a negative outcome is low (for 
example, after receiving a preventive intervention like HPV vaccination) may participate in 
less safe behaviors.[12, 13] Studies have shown that risk perceptions play an important role 
in sexual behaviors,[14–16] although studies of sexual behaviors following primary HIV 
prevention interventions have generally not demonstrated an increase in risky behaviors.[16, 
17] Because risk perceptions may influence behavior, it is critical to understand HPV 
vaccine-related risk perceptions and whether these perceptions impact behavior among 
adolescent girls who have been vaccinated against HPV.
To our knowledge, no studies have examined longitudinally the association between 
adolescent risk perceptions at the time of HPV vaccination and subsequent sexual behaviors 
and STI diagnosis. Data demonstrating that risk perceptions influence subsequent sexual 
behaviors or STI diagnoses may provide guidance for educational interventions that can be 
provided at the time of HPV vaccination. Therefore, the aim of the current study was to 
examine the associations between HPV vaccine-related risk perceptions and subsequent 
sexual behaviors and STI diagnosis over the 30 months following the first HPV vaccine dose 
among sexually experienced 13–21 year-old girls. We hypothesized that greater perceived 
need for safer sexual behaviors and greater perceived risk of STIs other than HPV would be 
associated with condom use at last sexual intercourse, fewer sexual partners, and fewer STI 
diagnoses.
 Methods
Data for this analysis were drawn from a longitudinal study of 339 13–21 year-old girls, 
consecutively recruited from an urban, hospital-based adolescent primary care office within 
2 days of receipt of their first HPV vaccine dose. Recruitment took place from 2008 to 2010, 
and participants were followed longitudinally until 2013. Consent was obtained from girls 
who were 18 years of age or older, and parental permission (in person or by phone) and 
assent from the girl was obtained for younger girls. Study staff contacted mothers or female 
legal guardians of all participants to invite them to enroll in the study; mothers provided 
consent for their participation. The study received approval from the hospital’s institutional 
review board.
Overall, 195 girls were sexually experienced at the baseline visit. Participants eligible for 
this analysis were the 112 sexually experienced girls who completed the baseline visit, the 
final 30-month visit, and at least 1 of the 3 intervening visits at 2, 6, and 18 months (i.e. 
completed at least 3 of 5 study visits, including the first and last study visits). Girls who 
were eligible for and included in this analysis differed from girls who were not eligible for 
this analysis by race (fewer white girls [8.0% of girls who were eligible for analysis vs. 
Mullins et al. Page 3
Vaccine. Author manuscript; available in PMC 2017 July 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15.7% of girls who were not eligible]; more black girls [88.4% of girls who were eligible for 
the analysis vs. 72.3% who were not eligible]; p=0.012) and reported number of lifetime 
sexual partners (28% of girls eligible for analysis vs. 14 % of girls not eligible for analysis 
reported 0–1 sexual partner; p=0.02); there were no significant differences in age, insurance 
status, reported condom use at last sexual intercourse with main male partner, smoking in 
the past month, lifetime alcohol use, or reported history of HPV or other STI. At each visit, 
girls completed self-administered surveys assessing HPV vaccine-related risk perceptions 
(perceived need for safer sexual behaviors, perceived risk of STIs other than HPV) and 
interim sexual behaviors. Sixty-two mothers completed surveys in person or by phone at 
baseline only. Survey constructs were derived from models of health behavior, including the 
Theory of Planned Behavior[18] and the Health Belief Model.[19] Specific items and scales 
assessing knowledge and attitudes were adapted from previously validated surveys in similar 
populations.[20] Primary predictor variables (HPV vaccine-related risk perceptions) were 
perceived risk of STIs other than HPV and perceived need for safer sexual behaviors, each 
of which was measured with a scale comprised of 5 items. Risk perceptions scales were 
adapted from scales measuring HIV/AIDS risk perceptions and HIV treatment attitudes.[21–
23] In order to capture risk perceptions related to HPV vaccination, each item was presented 
in the context of “getting vaccinated (the shot) against HPV” (see Table1, footnotes e and f). 
Responses to each of the 5 items were measured using a 10-point visual analog scale ranging 
from “strongly disagree” to “strongly agree”, with a neutral option in the middle of the scale. 
The mean response to all scale items was calculated, yielding a scale score which could 
range from 0–10. Higher scale scores indicated lower perceived risk of STIs and less 
perceived need for safer sexual behaviors; some scale items were reverse scored to maintain 
this interpretation. Mean scale scores were dichotomized for analysis into top tertile (lowest 
perceived risk of STIs, lowest perceived need for safer sexual behaviors) vs. lower two 
tertiles (greater perceived risk of STIs, greater perceived need for safer sexual behaviors) in 
order to examine the impact of the most risky attitudes on sexual behavior and STI 
diagnoses. Covariates included participant demographics, substance use (alcohol, marijuana, 
tobacco), HPV and HPV vaccine knowledge (10 items assessing knowledge of HPV[24] and 
three items assessing knowledge about the HPV vaccine), and patient reported lifetime 
history of HPV (including genital warts) or other STI at baseline. Maternal factors that were 
associated with perceived need for safer sexual behaviors among girls at baseline were 
entered as covariates as well. These were maternal knowledge about HPV and the HPV 
vaccine and maternal report of the source of HPV vaccine information (i.e., where mother 
obtained information about the HPV vaccine) and communication with the daughter about 
the HPV vaccine.[20] Outcomes were sexual behaviors and laboratory diagnosis of STIs 
over the 30 months following HPV vaccination, specifically: 1) condom use at last 
intercourse with main male partner (“condom use”)[25]; 2) number of sexual partners since 
last study visit (“sexual partners”); and 3) laboratory diagnosis of gonorrhea, chlamydia, 
and/or trichomonas at any visit (“positive STI testing”). Girls were tested for Neisseria 
gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis at the 6, 18, and 30 month 
visits.
Descriptive analyses were performed to examine participant characteristics, HPV vaccine-
related risk perceptions, sexual behaviors, and STI diagnosis. Linear mixed effects models 
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examined changes in HPV vaccine-related risk perceptions (perceived risk of STIs other 
than HPV and perceived need for safer sexual behaviors after vaccination) over the 30 
months of the study. The associations between predictor variables (i.e. perceived risk of 
other STIs other than HPV, perceived need for safer sexual behaviors), covariates, and sexual 
behaviors/STI outcomes were examined using generalized linear mixed effects models, 
which account for time-varying covariates. We examined separate univariable and 
multivariable models for each of the three outcomes (condom use, number of sexual 
partners, and positive STI testing). Predictors or covariates that were associated with an 
outcome at p<0.10 in univariable analyses were included in the multivariable mixed model 
for that outcome, and the variables remaining statistically significant at p<0.05 were retained 
in the final models.
 Results
 Demographics
For the girls included in this analysis, mean age was 17.9 years (SD 2.2). Nearly 90% of 
girls were self-reported Black, and 88% were insured. At baseline, 72% of girls reported 
having more than one male lifetime sexual partner, 54% had used a condom at last sex with 
their main male partner, and 49% had a history of HPV or another STI (Table 1). Girls 
whose mothers participated in the study were younger than girls whose mothers did not 
participate (mean age 16.8 vs. 19.3 years; p<0.0001). Over the 30 months of the study, 23–
55% of girls reported having more than one sexual partner between study visits, and 37–
50% of girls reported condom use with main male partner at last sexual intercourse. At each 
study visit, nearly 25% of girls had a positive STI test (Table 2).
 HPV Vaccine-Related Risk Perceptions
Overall, most girls still perceived themselves to be at risk for STIs other than HPV and 
perceived a continued need for safer sexual behaviors following HPV vaccination. Mean 
scale scores at baseline for these risk perception scales were as follows (lower numbers 
indicate higher perceived risk of STIs other than HPV and higher perceived need for safer 
sexual behaviors following vaccination): perceived risk of STIs 3.8 out of 10 (SD 1.96) and 
need for safer sexual behaviors 1.8 out of 10 (SD 1.8) (Table 1). Over the 30 months of the 
study, scale scores for perceived need for safer sexual behaviors did not change significantly. 
However, scale scores for perceived risk of STIs other than HPV decreased over time 
(p=0.027), indicating that girls perceived themselves to be more at risk of STIs other than 
HPV over the 30 months following HPV vaccination. Perceived risk of STIs other than HPV 
was not associated with having a diagnosed STI at the previous study visit (data not shown).
 Factors Associated with Condom Use
Greater perceived need for safer sexual behaviors was associated with girls’ use of a condom 
with main male partner at last sexual intercourse in univariable generalized linear mixed 
effects models. In contrast, perceived risk of STIs other than HPV was not associated with 
condom use with main male partner at last sexual intercourse. Covariates associated with 
condom use in univariable models at p<0.10 included younger age, no history of HPV or 
other STIs at baseline, maternal communication with the daughter about the HPV vaccine, 
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and having health insurance (Table 3). A multivariable mixed effects model demonstrated 
that greater perceived need for safer sexual behaviors was independently associated with 
condom use with the main male partner at last sexual intercourse when covariates were 
included in the model. Maternal report of communication with her daughter about the HPV 
vaccine also remained in the model.
 Factors Associated with Number of Sexual Partners
Univariable mixed effects models demonstrated that neither perceived need for safer sexual 
behaviors nor perceived risk of STIs other than HPV was associated with number of sexual 
partners since the last study visit. Covariates associated with number of sexual partners at 
p<0.10 included older age, history of smoking in the past 30 days, history of marijuana use, 
history of alcohol use, and history of HPV or other STI at baseline (Table 4). A multivariable 
mixed effects model demonstrated that older age and smoking in the past 30 days both 
remained independently associated with greater number of sexual partners since the last 
study visit.
 Factors Associated with Positive Testing for STIs
Univariable mixed effects models demonstrated that neither perceived need for safer sexual 
behaviors nor perceived risk of STIs other than HPV was associated with positive testing for 
STIs. Covariates associated with positive STI testing at p<0.10 included greater total number 
of sexual partners, older age, and history of marijuana use (Table 5). Multivariable mixed 
effects models showed that greater number of lifetime sexual partners remained 
independently associated with positive STI testing.
 Discussion
We examined the associations between HPV vaccine-related risk perceptions and subsequent 
sexual behaviors and STIs over the 30 months following the first HPV vaccination among 
13–21 year-old girls. We found that greater perceived need for safer sexual behaviors was 
associated in a multivariable model with condom use at last intercourse, but not with number 
of sexual partners or STI diagnosis, and that perceived risk of STIs was associated with 
neither sexual behaviors nor STI diagnosis. Although prior studies have examined 
associations between HPV vaccination and subsequent sexual behaviors and STIs,[26–28] 
this study is unique because it used individual-level data to examine longitudinally the 
association between HPV vaccine-related risk perceptions and subsequent sexual behaviors 
and STIs, and included maternal factors as covariates.
We found that adolescent girls who were sexually experienced at the time of HPV 
vaccination generally perceived themselves to be at risk of STIs other than HPV and 
believed that safer sexual behaviors were needed after vaccination. Additionally, rates of 
condom use remained fairly stable from baseline to 30 months. Prior cohort studies 
demonstrated no significant differences between vaccinated and unvaccinated girls and 
women with respect to age of sexual debut[27]; number of sexual partners[27, 29]; testing 
for or diagnosis of pregnancy or STI[26, 28] and counseling about contraception[26]; 
condom use[29]; and the proportion of girls who were sexually active.[29] Our previous 
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study of girls’ sexual behaviors in the first 6 months after HPV vaccination found no 
association between baseline HPV vaccine-related risk perceptions and sexual initiation or 
subsequent sexual behaviors.[30] Our current findings support and extend the results of 
these prior studies by 1) examining the association between risk perceptions and subsequent 
sexual behaviors and STI diagnosis, 2) assessing maternal factors associated with outcomes, 
and 3) demonstrating that over the 30 months following HPV vaccination, girls continued to 
perceive a need for safer sexual behaviors and perceived themselves to be more at risk of 
STIs other than HPV.
We examined the associations between risk perceptions after HPV vaccination and three 
different outcomes - condom use with main male partner at last sexual intercourse, number 
of sexual partners, and positive testing for STIs controlling for other sociodemographic and 
behavioral variables. As hypothesized, greater perceived need for safer sexual behaviors was 
associated with condom use at last sexual intercourse with the main male partner. In order to 
promote girls’ beliefs in the need for safer sexual behaviors post-vaccination, clinicians 
should educate sexually active girls who are receiving the HPV vaccine about the continued 
importance of condom use. On the other hand, we did not find evidence supporting an 
association between perceived risk of STIs after HPV vaccination and girls’ reported 
condom use at last sex. Maternal report of communication about the HPV vaccine was 
associated with condom use, which suggests that mothers may take the opportunity to 
discuss safer sexual behaviors when their daughter is being vaccinated against HPV.[31–33] 
In addition, mothers who discuss HPV vaccination with their daughters may be more likely 
to play an active role in educating their daughters about STI prevention. Because maternal 
report of communication with the daughter about the HPV vaccine was associated with 
condom use, clinicians should also encourage mothers to discuss sexual health topics, 
including HPV vaccination, with daughters. Such communication may be fostered by 
educating parents about the HPV vaccine and providing suggestions for how parents might 
approach sexual health topics with their children, as recommended by clinical care 
guidelines such as the American Academy of Pediatrics’ Bright Futures Guidelines.[34]
Neither of the HPV-vaccine related risk perceptions perceived need for safer sexual 
behaviors and perceived risk of STIs other than HPV - was associated with number of sexual 
partners since the last study visit. In our prior analysis of vaccine-related risk perceptions 
and sexual behaviors in the first 6 months following HPV vaccination, neither perceived risk 
of STIs other than HPV nor perceived need for safer sexual behaviors was associated with 
number of partners.[30] Our current results show that this lack of statistically significant 
association persists for 30 months following vaccination. Covariates that were independently 
associated with number of sexual partners since the last study visit included older age and 
recent smoking. Older girls are likely to have a greater number of partners as compared to 
younger girls as adolescents may accumulate more partners over time.[35] Recent smoking 
may be a marker for girls who are more likely to participate in riskier behaviors, such as 
having more sexual partners. Smoking has been associated with earlier onset of sexual 
activity, greater number of sexual partners, and other risky sexual behaviors.[36, 37]
Neither perceived need for safer sexual behaviors nor perceived risk of STIs other than HPV 
was associated with positive test results for STIs, providing further evidence that HPV 
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vaccine-related risk perceptions are not associated with riskier sexual behaviors. We 
included laboratory diagnosis of an STI as an outcome because this is an objective measure 
of risky sexual behavior that does not rely on self-report. Total number of sexual partners 
was the only predictor variable associated with positive STI results. This finding is not 
unexpected, as a greater number of sexual partners increases one’s risk of exposure to STIs 
and is one of the strongest predictors of STI diagnosis.[38, 39]
This study is subject to several limitations. First, participants were recruited from a medical 
practice that serves a low-income, urban population, which may limit the generalizability of 
the findings. Second, social desirability bias may have led to girls reporting higher perceived 
need for safer sexual behaviors. Third, due to our relatively small sample size, we may have 
had insufficient statistical power to detect associations between some variables. Fourth, 
participants who were not eligible for these analyses because they did not complete at least 3 
of the 5 study visits may have differed from those who did in terms of sexual behaviors and 
STI diagnosis. Fifth, no information about risk perceptions is available for these participants 
prior to their receipt of the first HPV vaccine dose. Therefore, we cannot examine changes 
between pre- and post-vaccination risk perceptions. Finally, we did not examine the risk 
perceptions of girls who did not receive the HPV vaccine; therefore, we cannot draw 
conclusions about differences in risk perceptions of vaccinated vs. unvaccinated girls.
 Conclusions
Over 30 months following receipt of the first HPV vaccine dose, most sexually experienced 
adolescent girls perceived themselves to be at continued risk of STIs other than HPV, and the 
vast majority of girls reported high perceived need to practice safer sexual behaviors. In 
general, HPV vaccine-related risk perceptions were not associated with subsequent sexual 
behaviors or STI diagnosis, which should provide reassurance to clinicians and parents. The 
finding that greater perceived need for safer sexual behaviors among girls and mothers’ 
communication with daughters about HPV vaccination were associated with condom use 
implies that clinicians and parents should educate girls about the continued need for safer 
sexual behaviors after HPV vaccination.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• The majority of girls perceived a need for safer sexual behaviors after 
vaccination.
• Most girls perceived themselves to be at risk for STIs other than HPV.
• Greater perceived need for safer sexual behaviors was associated with 
condom use.
• Perceived risk of STIs other than HPV was not associated with sexual 
behavior or STI.
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Table 1
Participant Characteristics and Covariates at Baseline
Characteristic Number (%) Mean (SD)
Age 17.9 (2.2)
Racea
 Black 99 (88)
 White 9 (8)
 Other 4 (4)
Have health insurance 98 (88)
Lifetime number of male sexual partnersb
 0–1 31 (28)
 2 or more 79 (72)
Condom use at last sex with main male partner 55 (54)
Smoking in the past month 19 (17)
Lifetime history of alcohol use 66 (59)
Participant reported lifetime history of HPV (including genital warts) or other STI 55 (49)
HPV and HPV vaccine knowledge scorec 5.4 (2.6)
Perceived risk of STI other than HPV after HPV vaccinationd,e 3.8 (2.0)
Perceived need for safer sexual behaviors after HPV vaccinationd,f 1.8 (1.8)
Maternal HPV and HPV vaccine knowledge scorec 6.6 (2.7)
Maternal report of communication with daughter about HPV vaccine 29 (47)
Maternal report that doctor is a source of information about the HPV vaccine 42 (68)
SD=standard deviation; HPV=human papillomavirus; STI=sexually transmitted infection
a
Race was self-reported.
b
Two participants did not answer this question.
c
The total possible score ranged from 0–13. The scale consisted of 10 items assessing knowledge of HPV [20] and three items assessing knowledge 
about the HPV vaccine (i.e., need for Pap testing after vaccination, vaccine protects against all cervical cancer, and vaccine protects against all HPV 
associated with cancer).
d
For both perceived risk of STI other than HPV and perceived need for safer sexual behaviors, the possible range of mean scale scores was 0–10, 
with higher scale scores indicate riskier attitudes. For example, a higher mean scale score for perceived risk of STIs indicates lower perceived risk 
of STIs other than HPV after vaccination, and a higher mean scale score for perceived need for safer sexual behaviors indicates lower perceived 
need for safer sexual behaviors following HPV vaccination.
eSpecific items comprising this scale included: “After getting vaccinated (the shot) against HPV… 1) I am less worried about getting a sexually 
transmitted infection or disease (STI or STD) other than HPV; 2) I am still just as concerned about getting an STI or STD other than HPV; 3) I 
think getting an STI or STD other than HPV will be less of a problem; 4) I am less worried that one of my sex partners could get an STI or STD 
other than HPV from me; and 5) There is less of a chance that I will get an STI other than HPV than there used to be.”
fSpecific items comprising this scale included: “After getting vaccinated (the shot) against HPV… 1) I think that condom use during sex is less 
necessary; 2) I feel it is still just as important to have as few sexual partners as possible; 3) I feel that it is not as important to talk to my sex partners 
about safe sex; 4) I think it is still just as important to use condoms every time I have sex; and 5) I will be less worried about having unprotected 
sex.”
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